Editorial introductions : Current Opinion in Oncology

Secondary Logo

Journal Logo

Editorial introductions

Editorial introductions

doi: 10.1097/CCO.0b013e32832d41ee
  • Free

Current Opinion in Oncology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of psychiatry is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.

Section Editors

Jean Klastersky

FU1-2
Figure 1

Professor Klastersky has been head of the department of medicine at the Institut Jules Bordet in Brussels and Professor of Medicine, Medical Oncology and Physical Diagnosis at the Université Libre de Bruxelle,s since 1977.

He retired from these positions in 2005. Currently, he is the Coordinator of the “Programme des Soins Oncologiques” for the Public Hospitals in Brussels and Consultant in medical oncology at the Institut Jules Bordet.

Professor Klastersky was an intern and resident at the University Hospitals of the Université Libre de Bruxelles between 1962 and 1965, where he gained his MD (Docteur en Médecine, Chirurgie et Accouchements). From 1967 to 1968, he was Chief-Resident at Boston City Hospital and then a Research Fellow and Assistant in Medicine at Thorndike Memorial Laboratory, Harvard Medical School. He became Chief of the Section of Infectious Diseases at the Institut Jules Bordet in 1970, before taking up the position of Head of the Department of Medicine in 1977.

Professor Klastersky was a founder member of the European Lung cancer Working Party and has been its president since 1978 until 2003. He was president (and founder member) of the International EORTC Antimicrobial Therapy Project Group between 1979 and 1987 and the group's secretary general from 1987 to 2000. He was president (and founder member) of the Multinational Association for Supportive Care in Cancer (MASCC) from 1990 to 2000. He is Visiting Professor of Medical Oncology at the Charles University in Prague, since 1994.

Professor Klastersky is a member of the American Society of Clinical Oncology, the American Association of Cancer Research, the European Society of Medical Oncology, the American Society of Microbiology, the Infectious Diseases Society of America, the International Association for the Study of Lung Cancer, the “Royale Académie de Médecine” of Belgium; and various other international and national medical and/or oncological societies.

Professor Klastersky is the author of over 400 original articles, nearly 400 review articles and 17 scientific books. He is the Editor of Current Opinion in Oncology.

Jonathan Trent

FU2-2
Figure 2

Jonathan C. Trent, MD, PhD is an assistant internist and professor of medicine in the Department of Sarcoma Medical Oncology, Division of Cancer Medicine at The University of Texas, M. D. Anderson Cancer Center in Houston, Texas.

Dr Trent has published numerous abstracts and research articles in leading journals, as well as book chapters, and is a frequently requested lecturer on the topic of gastrointestinal stromal tumor (GIST). His funding for his GIST research is obtained from the NIH as well as private foundations. He is on the editorial board of the Chinese Journal of Clinical Oncology and has served as a reviewer on a number of journals, including The Proceedings of the National Academy of Science, Lancet, Nature Biotechnology, Cancer, Clinical Cancer Research, and Cancer Research, and has received a number of honors for his work in GIST research. His clinical interests include sarcoma, clinical trials, novel therapies, and translational research. He is the principal investigator, as well as a collaborator, on numerous clinical trials for GIST. Ongoing trials are examining the use of imatinib mesylate (Gleevec®) alone and in combination with novel drugs in patients with metastatic GIST and the combination of imatinib with surgery in resectable GIST.

Dr Trent earned his undergraduate degree in chemistry at Southeastern Oklahoma State University and his MD and PhD in cancer biology from The University of Texas Health Science Center. He completed an internship and residency in internal medicine at The University of Texas Health Science Center, and a fellowship in medical oncology at The University of Texas, MD Anderson Cancer Center. Dr Trent is board certified in internal medicine and medical oncology.

Alain Hendlisz

FU3-2
Figure 3

Doctor Alain Hendlisz is a gastro-enterologist. He gained his MD (Docteur en Médecine, Chirurgie et Accouchements) at the Université Libre de Bruxelles in 1988 and is specialist in gastro-enterology since 1993.

He is currently Head of the Gastro-Enterology Unit at the Jules Bordet Institute, Anti-Cancer Center – Brussels – Belgium.

He is founding and currently member of the Board of the BGDO (Belgian Group for Digestive Oncology). He is a member of the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), the Société Royale Belge de Gastro-entérologie (SRBG) and European Organization for Research and Treatment of Cancer (EORTC).

He is involved as principal investigator or co-investigator in numerous national and international clinical studies.

© 2009 Lippincott Williams & Wilkins, Inc.